


Practitioner's Docket No. MPI01-026P1RNM



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rosana Kapeller-Libermann

Application No.: 10/056,744

Group No.: 1646

Filed: January 25, 2002

Examiner: N/A

For: 58860, A HUMAN CHOLESTERYL ESTER HYDROLASE AND USES THEREFOR

RECEIVED

JUN 24 2002

TECH CENTER 1600-2900

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
3. ☒ Copies of Listed Information Items Accompanying This Statement

§§

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Simonne Corriveau

(type or print name of person certifying)

Date: June 13, 2002

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

June 13, 2002

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|-----------------------------|---------------------------|-------------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/056,744 | | |
| | | Filing Date | January 25, 2002 | | |
| | | First Named Inventor | Rosana Kapeller-Libermann | | |
| | | Group Art Unit | 1646 | | |
| | | Examiner Name | N/A | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | MPI01-026P1RNM |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | AD | CARNINI, P. et al "Mus musculus adult male stomach cDNA, RIKEN full-length enriched library, clone:2210418G03:homolog to LYSOSOMAL ACID LIPASE, full insert sequence" 19 January 2002 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on June 6, 2002]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AK008974. | |
| | AE | ASHWELL, R., "Human DNA sequence from clone RP11-186014 on chromosome 10, complete sequence" 15 December 2000 (sequence) GenBank [online] Bethesda, MD USA: National Center for Biotechnology Information [retrieved on June 6, 2002]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/ >. GenBank Accession No. AL358532. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|---------------------------|--|------------------------|--|
| Examiner Signature | | Date Considered | |
|---------------------------|--|------------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

JUN 24 2002

TECH CENTER 1600 2900